Insulet to Present at Upcoming Investor Conferences

Rhea-AI Summary

Insulet (NASDAQ: PODD), the global leader in tubeless insulin pump technology, has announced its participation in three upcoming investor conferences in September 2024:

• The 2024 Wells Fargo Healthcare Conference in Boston on September 4 at 9:30 a.m. ET
• The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on September 6 at 8:30 a.m. ET
• The Baird 2024 Global Healthcare Conference in New York City on September 10 at 8:30 a.m. ET

Live audio webcasts of the presentations will be available on the company's investor relations website. Insulet is known for its Omnipod Insulin Management System, a tubeless disposable Pod that provides up to three days of non-stop insulin delivery. The company's flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor and can be controlled by a compatible smartphone in the U.S.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time):

• The 2024 Wells Fargo Healthcare Conference in Boston on Wednesday, September 4, 2024 at 9:30 a.m.
• The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Friday, September 6, 2024 at 8:30 a.m.
• The Baird 2024 Global Healthcare Conference in New York City on Tuesday, September 10, 2024 at 8:30 a.m.

To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will also be available following the events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240815501629/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

When and where will Insulet (PODD) present at investor conferences in September 2024?

Insulet (PODD) will present at three investor conferences in September 2024: The Wells Fargo Healthcare Conference in Boston on September 4, the Morgan Stanley Global Healthcare Conference in New York City on September 6, and the Baird Global Healthcare Conference in New York City on September 10.

What is Insulet's (PODD) main product for diabetes management?

Insulet's (PODD) main product is the Omnipod Insulin Management System, a tubeless disposable Pod that provides up to three days of non-stop insulin delivery without the need for multiple daily injections or fingersticks.

How can investors access Insulet's (PODD) presentations at the upcoming conferences?

Investors can access live audio webcasts of Insulet's (PODD) presentations at the upcoming conferences by visiting the company's investor relations website at investors.insulet.com/events. Replays of the webcasts will also be available following the events.

What is unique about Insulet's (PODD) Omnipod 5 Automated Insulin Delivery System?

Insulet's (PODD) Omnipod 5 Automated Insulin Delivery System is a tubeless automated insulin delivery system that integrates with a continuous glucose monitor. It can be fully controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller, requiring no multiple daily injections or fingersticks.